Sana Biotechnology logo

Sana Biotechnology

sana.com

Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.

Facts

Sectors
Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
Type
Corporation Seattle business license
Registered name
Sana Biotechnology Inc Seattle business license
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

Sana Biotechnology says SC451 Phase 1/2 and SG293 clinical studies nearing start; Q2 cash $160.5M, runway into mid-2027

Sana Biotechnology reported Q2 2026 progress toward initiating Phase 1/2 trial for SC451 in type 1 diabetes and a clinical study for SG293 in non-Hodgkin lymphoma, highlighted by NEJM publication and upcoming EASD presentation for UP421 clinical data. The company presented SG293 and SG227 preclinical data, advanced a Mayo Clinic collaboration, and reported $160.5M cash with runway into mid-2027.

People

  • Steve Harr Co-founder and President and Chief Executive Officer
  • Snehal Patel Executive, Executive Vice President and Chief Technical Officer

Online